BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24478055)

  • 1. Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies.
    Alemán JO; Farooki A; Girotra M
    Endocr Relat Cancer; 2014 Jun; 21(3):R247-59. PubMed ID: 24478055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
    Deininger MW; Manley P
    Leuk Res; 2012 Mar; 36(3):253-61. PubMed ID: 21996558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
    Breccia M; Alimena G
    Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
    Rohon P; Porkka K; Mustjoki S
    Eur J Haematol; 2010 Nov; 85(5):387-98. PubMed ID: 20662899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
    Nasr R; Bazarbachi A
    Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
    Giles FJ; O'Dwyer M; Swords R
    Leukemia; 2009 Oct; 23(10):1698-707. PubMed ID: 19474800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.
    le Coutre P; Schwarz M; Kim TD
    Clin Cancer Res; 2010 Mar; 16(6):1771-80. PubMed ID: 20197479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
    Ault P
    Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
    Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
    Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.
    Tibullo D; Barbagallo I; Giallongo C; La Cava P; Branca A; Conticello C; Stagno F; Chiarenza A; Palumbo GA; Di Raimondo F
    Hematol Oncol; 2012 Mar; 30(1):27-33. PubMed ID: 21544849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The skeletal effects of the tyrosine kinase inhibitor nilotinib.
    O'Sullivan S; Lin JM; Watson M; Callon K; Tong PC; Naot D; Horne A; Aati O; Porteous F; Gamble G; Cornish J; Browett P; Grey A
    Bone; 2011 Aug; 49(2):281-9. PubMed ID: 21550432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.